{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T17:23:43Z","timestamp":1783099423845,"version":"3.54.6"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Gut microbiota has demonstrated an increasingly important role in the onset and development of type 2 diabetes mellitus (T2DM), Further investigations have revealed the interactions between drugs and the gut microbiome. However, there are still gaps in research regarding the potential interactions between the gut microbiota and GLP-1 and their therapeutic response in people with T2DM. In addition, Fecal microbiota transplantation (FMT) has become a promising strategy for patients with T2DM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, animals and measurements<\/jats:title><jats:p>50 healthy male C57BL\/6 mice were fed a high-fat diet in combination with STZ to establish a T2DM mouse model. 40 mice were divided into the T2DM group (n=10) and the PEX168 group (n=30). the PEX168 group was divided into two subgroups of the IE group (HbA1c \u22646. 5%, n=12) and the SE group (HbA1c &amp;gt;6. 5%, n=12), 12 mice in each group. Using IE mice as fecal donors and SE mice as recipients, fecal microbiota transplantation was performed between the two groups, the FMT group (given fecal bacterial suspension, n=5) and the Sham group (given equal amounts of sterile saline, n=5). The intestinal microorganisms of mice in the IE group (donor) and SE group (recipient) were also analyzed for differences. To assess the protective effect of FMT on drug efficacy and T2DM, and to explore the underlying mechanisms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After 10 weeks, compared with the control group, the HbA1c of the experimental group was significantly reduced, still, the level of HBA1c of the mice in the unsatisfactory group was significantly higher than that in the ideal group. Compared with the unsatisfactory group, fasting blood glucose, 2h postprandial blood glucose, blood glucose AUC and body weight were significantly reduced in the ideal group. 16srDNA sequencing showed that the levels of Bacteroidota, Akkermansia, Parabacteroides, Bifidobacteria and other bacteria in the ideal efficacy group were significantly higher than those in the non-ideal efficacy group (P&amp;lt;0.05). The levels of Firmicutes, Romboutsia, Clostridium, Turicibacter and other bacteria in the unsatisfactory group were significantly higher than those in the ideal group (P&amp;lt;0.05). The dominant flora of mice in the ideal drug efficacy group was negatively correlated with HbA1c and blood sugar, and the dominant flora of mice in the unsatisfactory drug efficacy group was positively correlated with pro-inflammatory factors such as blood sugar. Moreover, FMT treatment significantly improved the efficacy of PEX168 and liver steatosis in the group with unsatisfactory efficacy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In summary, we used the combined method of 16S rDNA and metabolomics to systematically elucidate the efficacy of microflora on PEX168 and the possible mechanism of FMT in treating T2DM by PEX168. The difference in intestinal flora between individuals can affect the therapeutic effect of drugs. Moreover, FMT therapy can affect multiple metabolic pathways and colonization of beneficial bacteria to maintain the drug\u2019s therapeutic effect on T2DM mice.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2025.1508473","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:12:10Z","timestamp":1750306330000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Animal studies on the modulation of differential efficacy of polyethylene glycol loxenatide by intestinal flora"],"prefix":"10.3389","volume":"16","author":[{"given":"Dang","family":"Wenjiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Yurou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xie","family":"Jiaqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Hongfang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Jianjin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41401-019-0330-9","article-title":"Fecal microbiota transplantation improves metabolism and gut microbiome composition in db\/db mice","volume":"41","author":"Zhang","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"Jama"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System","volume":"60","author":"Fadini","year":"2017","journal-title":"Diabetologia"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0923","article-title":"Reports of lactic acidosis attributed to metformin, 2015-2018","volume":"43","author":"Flory","year":"2020","journal-title":"Diabetes Care"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7150\/thno.86831","article-title":"Targeting redox imbalance in neurodegeneration: characterizing the role of GLP-1 receptor agonists","volume":"13","author":"Ghosh","year":"2023","journal-title":"Theranostics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2147\/dmso.S312527","article-title":"An overview of similarities and differences in metabolic actions and effects of central nervous system between glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium glucose co-transporter-2 inhibitors (SGLT-2is)","volume":"14","author":"Wen","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/dom.14496","article-title":"The evolving story of incretins (GIP and GLP-1) in metabolic and cardiovascular disease: A pathophysiological update","author":"Nauck","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"B9","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1007\/BF00291980","article-title":"Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets","volume":"28","author":"Schmidt","year":"1985","journal-title":"Diabetologia"},{"key":"B10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1042\/cs20171299","article-title":"Cardiovascular benefits of GLP-1 agonists in type 2 diabetes: a comparative review","volume":"132","author":"Boyle","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23071564","article-title":"Influence of diet and gender on plasma DPP4 activity and GLP-1 in patients with metabolic syndrome: an experimental pilot study","volume":"23","author":"Francisco","year":"2018","journal-title":"Molecules"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01637-6","article-title":"Efficacy and safety of glucagon-like peptide\u20021 receptor agonists for the treatment of type\u20022 diabetes mellitus: A network meta-analysis","volume":"38","author":"Jiang","year":"2021","journal-title":"Adv Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0470-y","article-title":"Glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy adherence for patients with type 2 diabetes in a medicare population","volume":"34","author":"Nguyen","year":"2017","journal-title":"Adv Ther"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.S151736","article-title":"Adherence to antihyperglycemic medications and glucagon-like peptide 1-receptor agonists in type 2 diabetes: clinical consequences and strategies for improvement","volume":"12","author":"Giorgino","year":"2018","journal-title":"Patient Prefer Adherence"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326789","article-title":"Gut microbiome and health: mechanistic insights","volume":"71","author":"de Vos","year":"2022","journal-title":"Gut"},{"key":"B17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41579-020-0433-9","article-title":"Gut microbiota in human metabolic health and disease","volume":"19","author":"Fan","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0407076101","article-title":"The gut microbiota as an environmental factor that regulates fat storage","volume":"101","author":"B\u00e4ckhed","year":"2004","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/jas\/skaa030","article-title":"Dietary phytonutrients and animal health: regulation of immune function during gastrointestinal infections","volume":"98","author":"Williams","year":"2020","journal-title":"J Anim Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/j.cmet.2017.04.013","article-title":"A specific gut microbiota dysbiosis of type 2 diabetic mice induces GLP-1 resistance through an enteric NO-dependent and gut-brain axis mechanism","volume":"25","author":"Grasset","year":"2017","journal-title":"Cell Metab"},{"key":"B21","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/PPA.s82866","article-title":"Mode of administration of dulaglutide: implications for treatment adherence","volume":"10","author":"Amblee","year":"2016","journal-title":"Patient Preference Adherence"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-8587(22)00387-4","article-title":"Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial","volume":"11","author":"Laffel","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00455","article-title":"Promising treatment for type 2 diabetes: fecal microbiota transplantation reverses insulin resistance and impaired islets","volume":"9","author":"Wang","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1039\/c6fo01196a","article-title":"Protective effects of Angelica sinensis polysaccharide against hyperglycemia and liver injury in multiple low-dose streptozotocin-induced type 2 diabetic BALB\/c mice","volume":"7","author":"Wang","year":"2016","journal-title":"Food Funct"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.836542","article-title":"Human fecal microbiota transplantation reduces the susceptibility to dextran sulfate sodium-induced germ-free mouse colitis","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0233872","DOI":"10.1371\/journal.pone.0233872","article-title":"Alpha-, beta-, and gamma-diversity of bacteria varies across habitats","volume":"15","author":"Walters","year":"2020","journal-title":"PloS One"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.943427","article-title":"Gut microbiota composition in prediabetes and newly diagnosed type 2 diabetes: A systematic review of observational studies","volume":"12","author":"Letchumanan","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1080\/03602532.2020.1718691","article-title":"The metabolic effect of gut microbiota on drugs","volume":"52","author":"Xie","year":"2020","journal-title":"Drug Metab Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-017-0986-y","article-title":"Impact of gut microbiota on drug metabolism: an update for safe and effective use of drugs","volume":"40","author":"Noh","year":"2017","journal-title":"Arch Pharm Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes","volume":"106","author":"Thomas","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol Metab"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet"},{"key":"B33","first-page":"1097","article-title":"Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss","volume":"39","author":"Iepsen","year":"2014","journal-title":"Int J Obes"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcd.2011.09.002","article-title":"Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction","volume":"6","author":"Lind","year":"2012","journal-title":"Prim Care Diabetes"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155710","article-title":"Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials","volume":"149","author":"Karakasis","year":"2023","journal-title":"Metabolism"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2337\/ds20-0025","article-title":"Exploring why people with type 2 diabetes do or do not persist with glucagon-like peptide-1 receptor agonist therapy: A qualitative study","volume":"34","author":"Polonsky","year":"2021","journal-title":"Diabetes Spectr"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/s41467-017-01682-2","article-title":"Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment","volume":"8","author":"Gu","year":"2017","journal-title":"Nat Commun"},{"key":"B38","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.trsl.2021.03.016","article-title":"Long-chain monounsaturated fatty acids improve endothelial function with altering microbial flora","volume":"237","author":"Tsutsumi","year":"2021","journal-title":"Transl Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e1007581","DOI":"10.1371\/journal.ppat.1007581","article-title":"Bile salt hydrolases: Gatekeepers of bile acid metabolism and host-microbiome crosstalk in the gastrointestinal tract","volume":"15","author":"Foley","year":"2019","journal-title":"PloS Pathog"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.9b08231","article-title":"Role of the microbiome in mediating health effects of dietary components","volume":"68","author":"Gong","year":"2020","journal-title":"J Agric Food Chem"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00933-y","article-title":"Antibiotic perturbations to the gut microbiome","volume":"21","author":"Fishbein","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-1321","article-title":"Bile acids trigger GLP-1 release predominantly by accessing basolaterally located G protein-coupled bile acid receptors","volume":"156","author":"Brighton","year":"2015","journal-title":"Endocrinology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323297","article-title":"Duodenal Anaerobutyricum soehngenii infusion stimulates GLP-1 production, ameliorates glycaemic control and beneficially shapes the duodenal transcriptome in metabolic syndrome subjects: a randomised double-blind placebo-controlled cross-over study","volume":"71","author":"Koopen","year":"2022","journal-title":"Gut"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-021-00880-5","article-title":"Akkermansia muciniphila secretes a glucagon-like peptide-1-inducing protein that improves glucose homeostasis and ameliorates metabolic disease in mice","volume":"6","author":"Yoon","year":"2021","journal-title":"Nat Microbiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.micpath.2017.07.034","article-title":"The association of type II diabetes with gut microbiota composition","volume":"110","author":"Navab-Moghadam","year":"2017","journal-title":"Microb Pathog"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2020.01.305","article-title":"Intestinal microbes derived butyrate is related to the immunomodulatory activities of Dendrobium officinale polysaccharide","volume":"149","author":"Li","year":"2020","journal-title":"Int J Biol Macromol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00394-021-02520-4","article-title":"Manipulation of intestinal microbiome as potential treatment for insulin resistance and type 2 diabetes","volume":"60","author":"Ghorbani","year":"2021","journal-title":"Eur J Nutr"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.carbpol.2020.116261","article-title":"Odd-numbered agaro-oligosaccharides alleviate type 2 diabetes mellitus and related colonic microbiota dysbiosis in mice","volume":"240","author":"Wang","year":"2020","journal-title":"Carbohydr Polym"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.0c00605","article-title":"Hypoglycemic effect of ginsenoside rg5 mediated partly by modulating gut microbiota dysbiosis in diabetic db\/db mice","volume":"68","author":"Wei","year":"2020","journal-title":"J Agric Food Chem"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1039\/d0fo01720e","article-title":"Lactobacillus rhamnosus LRa05 improves lipid accumulation in mice fed with a high fat diet via regulating the intestinal microbiota, reducing glucose content and promoting liver carbohydrate metabolism","volume":"11","author":"Sun","year":"2020","journal-title":"Food Funct"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jafc.1c02925","article-title":"Lactobacillus rhamnosus LRa05 Ameliorate Hyperglycemia through a Regulating Glucagon-Mediated Signaling Pathway and Gut Microbiota in Type 2 Diabetic Mice","volume":"69","author":"Wu","year":"2021","journal-title":"J Agric Food Chem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.632335","article-title":"Modulating the microbiota as a therapeutic intervention for type 2 diabetes","volume":"12","author":"Huda","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13561","article-title":"Gut microbiota and obesity: An opportunity to alter obesity through faecal microbiota transplant (FMT)","volume":"21","author":"Lee","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1038\/s41467-018-07359-8","article-title":"Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells","volume":"9","author":"Burrello","year":"2018","journal-title":"Nat Commun"},{"key":"B55","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1053\/j.gastro.2020.08.041","article-title":"Effects of diet-modulated autologous fecal microbiota transplantation on weight regain","volume":"160","author":"Rinott","year":"2021","journal-title":"Gastroenterology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11892-019-1180-z","article-title":"Fecal microbiota transplantation: a future therapeutic option for obesity\/diabetes","volume":"19","author":"Aron-Wisnewsky","year":"2019","journal-title":"Curr Diabetes Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2019.12.010","article-title":"Fecal microbiota transplantation in disease therapy","volume":"503","author":"Antushevich","year":"2020","journal-title":"Clin Chim Acta"},{"key":"B58","doi-asserted-by":"crossref","first-page":"1089991","DOI":"10.3389\/fcimb.2022.1089991","article-title":"Fecal microbiota transplantation reverses insulin resistance in type 2 diabetes: A randomized, controlled, prospective study","volume":"12","author":"Wu","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.108005","article-title":"Activation of a specific gut bacteroides-folate-liver axis benefits for the alleviation of nonalcoholic hepatic steatosis","volume":"32","author":"Qiao","year":"2020","journal-title":"Cell Rep"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1508473\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T04:12:11Z","timestamp":1750306331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1508473\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,19]]},"references-count":59,"alternative-id":["10.3389\/fendo.2025.1508473"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1508473","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,19]]},"article-number":"1508473"}}